title: Bone morphogenetic proteins are involved in the pathobiology of synovial chondromatosis.
abstract: Synovial chondromatosis is characterized by the formation of osteocartilaginous nodules (free bodies) under the surface of the synovial membrane in joints. Free bodies and synovium isolated from synovial chondromatosis patients expressed high levels of BMP-2 and BMP-4 mRNAs. BMP-2 stimulated the expression of Sox9, Col2a1, and Aggrecan mRNAs in free-body and synovial cells and that of Runx2, Col1a1, and Osteocalcin mRNAs in the synovial [corrected] cells only. BMP-2 increased the number of alcian blue-positive colonies in the free-body cell culture but not in the synovial cell culture. Noggin suppressed the expression of Sox9, Col2a1, Aggrecan, and Runx2 mRNAs in both the free-body and synovial cells. Further, it inhibited Osteocalcin expression in the synovial cells. These results suggest that BMPs are involved in the pathobiology of cartilaginous and osteogenic metaplasia observed in synovial chondromatosis.
authors.affiliation: Section of Oral Pathology, Graduate School of Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8549, Japan.
authors.forename: Shoichi
authors.initials: S
authors.lastname: Nakanishi
authors.forename: Kei
authors.initials: K
authors.lastname: Sakamoto
authors.forename: Kei
authors.initials: K
authors.lastname: Sskamoto
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yoshitake
authors.forename: Koji
authors.initials: K
authors.lastname: Kino
authors.forename: Teruo
authors.initials: T
authors.lastname: Amagasa
authors.forename: Akira
authors.initials: A
authors.lastname: Yamaguchi
mesh_terms: D053674:Aggrecans / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D055396:Bone Morphogenetic Protein 2 / Q000494:pharmacology; D019485:Bone Morphogenetic Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000494:pharmacology; D002352:Carrier Proteins / Q000494:pharmacology; D002358:Cartilage, Articular / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002478:Cells, Cultured; D015838:Chondromatosis, Synovial / Q000378:metabolism* / Q000473:pathology*; D024043:Collagen Type II / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D050659:Core Binding Factor Alpha 1 Subunit / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D006801:Humans; D015675:Osteocalcin / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D011994:Recombinant Proteins / Q000494:pharmacology; D055758:SOX9 Transcription Factor / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D000099176:Noggin Protein
chemical_list: D053674:Aggrecans; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D002352:Carrier Proteins; D024043:Collagen Type II; D050659:Core Binding Factor Alpha 1 Subunit; D015675:Osteocalcin; D011994:Recombinant Proteins; D055758:SOX9 Transcription Factor; D016212:Transforming Growth Factor beta; D000099176:Noggin Protein; C525718:BMP2 protein, human; C499177:COL2A1 protein, human; C493709:RUNX2 protein, human; C527932:SOX9 protein, human; C499469:recombinant human bone morphogenetic protein-2